Shares of LataMed AI Corp. (LMED) surged 16.3% to $0.99 on July 15, but the rally masks a deeper structural story: the company's 5-for-1 forward stock split and mandatory share exchange, effective with July trading, has mechanically slashed the per-share price from its pre-split equivalent of roughly $4.25 — leaving LMED trading under the psychologically critical $1 mark and raising fresh questions about its listing status and investor appeal. LataMed AI's 5-for-1 Split Pushes Shares Under a Dollar — Is This a Liquidity Play or a Dilution Trap for Investors?

Shares of LataMed AI Corp. (OTC: LMED) jumped 16.3% to $0.99 on July 15, but the bounce comes against the backdrop of a stock that has lost roughly 77% of its per-share value since a 5-for-1 forward stock split took effect in early July. That decline is largely mechanical — each old share became five cheaper ones — not a business implosion. But the move has created real confusion and real risk for shareholders of this development-stage company that still generates zero revenue.

• The Split Itself Didn't Destroy Value, but It Changed the Math

On July 2, LataMed filed a Certificate of Change with Nevada to expand authorized common shares from 700 million to 3.5 billion and preferred shares from 300 million to 1.5 billion.

Each existing share was reclassified into five, increasing share liquidity but also reshaping the capital structure with "potential implications for investor perception and future capital-raising flexibility." That last phrase is the quiet part said loud: a company with 3.5 billion authorized shares and no revenue has given itself enormous room to issue new stock and dilute existing holders.

• A Sub-Dollar Price Invites the Wrong Kind of Attention Trading below $1.00 on the OTC market puts LMED squarely in penny-stock territory, where volatile day-trading, thin order books, and broker restrictions on purchasing can amplify swings in both directions. Message board chatter already shows single-share trades dominating the tape , a hallmark of speculative micro-cap noise rather than institutional interest.

• The PR Blitz Outpaces the Business Reality In just the first two weeks of July, LataMed announced a telecom alliance in Venezuela, a Colombia expansion study, and a CEO recognition event — a flurry of headlines for a company that has "not generated revenues from its current business operations."

Its Venezuelan affiliate signed a deal with state-run telecom CANTV to distribute its healthcare app , but implementation will occur in phases with no disclosed timeline or economics.

• Where This Leaves Shareholders

The company only changed its name to LataMed AI from Catalyst Crew Technologies in April 2026 , and describes itself as a "development-stage" digital health company focused on emerging markets. Investors now hold five times more shares at one-fifth the price, in a company with a massively expanded authorized share count and no clear path to revenue. The 16% rally may feel encouraging, but until the business generates real income, the split looks less like a growth signal and more like a blank check.